Mubadala's Venture Crew Targets New Frontier in Biotech Drug Development.
Mubadala's venture group is focusing on protein degradation, a new modality in drug discovery, after Rami Hannoush's meeting with UCSF's Jim Wells. FDA advisors unanimously recommended accelerated approval for Biogen's ALS drug tofersen, despite it failing its Phase III study. Genentech is halting commercial manufacturing at its California headquarters and laying off several hundred employees. A new study finds that patient influencers are sharing prescription drug experiences along with health information. Novartis is calling off a UK-based trial for Leqvio in the primary prevention of cardiovascular events in patients with high cholesterol.